Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe
in the treatment of relapsed or refractory Hodgkin's Lymphoma.